Premium
Alvimopan, a selective peripherally acting μ ‐opioid antagonist *
Author(s) -
Camilleri M.
Publication year - 2005
Publication title -
neurogastroenterology and motility
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.489
H-Index - 105
eISSN - 1365-2982
pISSN - 1350-1925
DOI - 10.1111/j.1365-2982.2005.00640.x
Subject(s) - medicine , constipation , ileus , antagonist , opioid , anesthesia , nausea , clinical pharmacology , intestinal motility , opiate , opioid antagonist , pharmacology , motility , gastroenterology , (+) naloxone , receptor , biology , genetics
Alvimopan is a novel, peripherally acting μ ‐opioid antagonist that is being developed for the management of acute postoperative ileus and for the reversal of the delayed gastrointestinal and colonic transit that result in symptoms such as constipation, nausea and motility disorders in patients treated with opiate analgesics. There is a clinical need for effective medications for the treatment of postoperative ileus and opiate‐induced constipation and other motility disorders. This review addresses the basic and applied pharmacology and current evidence for the use of the medication, alvimopan, in clinical gastroenterology.